Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cytosorbents Corporation - Common Stock (NQ: CTSO )

1.150 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cytosorbents Corporation - Common Stock

< Previous 1 2 Next >
CytoSorbents Strengthens Balance Sheet with Closing of Oversubscribed Rights Offering
From CytoSorbents
Via GlobeNewswire
CytoSorbents Expands Global Footprint with Opening of New Regional Sales Subsidiary in Dubai
From CytoSorbents
Via GlobeNewswire
CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2024 Product Revenue
From CytoSorbents
Via GlobeNewswire
CytoSorbents Rights Offering Begins
To Participate, Eligible Stockholders Should Consult Their Broker or Financial Advisor in Advance of the Rights Offering Expiration on January 10, 2025 
From CytoSorbents
Via GlobeNewswire
CytoSorbents to Host Investor Meetings in San Francisco During J.P. Morgan Healthcare Conference Week
From CytoSorbents
Via GlobeNewswire
CytoSorbents Announces Rights Offering
Investors Must Hold or Buy CTSO Common Stock by Close of Nasdaq Trading on Friday, December 13, 2024 to Participate 
From CytoSorbents
Via GlobeNewswire
CytoSorbents to Participate at the Piper Sandler 36th Annual Healthcare Conference
From CytoSorbents
Via GlobeNewswire
CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India
From CytoSorbents; Converge Biotech
Via GlobeNewswire
CytoSorbents Reports Third Quarter 2024 Financial and Operational Results
From CytoSorbents
Via GlobeNewswire
CytoSorbents Submits Health Canada Medical Device License Application for DrugSorb-ATR Following MDSAP Certification
From CytoSorbents
Via GlobeNewswire
FDA Accepts DrugSorb-ATR De Novo Application To Reduce the Severity of CABG-Related Bleeding Due to Ticagrelor and Initiates Substantive Review
DrugSorb™-ATR is an FDA Breakthrough Device eligible for priority review with an FDA decision anticipated in 2025 
From CytoSorbents
Via GlobeNewswire
CytoSorbents to Report Third Quarter 2024 Operating and Financial Results
From CytoSorbents
Via GlobeNewswire
CytoSorbents Submits DrugSorb-ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor and Provides Business Update
From CytoSorbents
Via GlobeNewswire
CytoSorbents to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference
From CytoSorbents
Via GlobeNewswire
CytoSorbents Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From CytoSorbents
Via GlobeNewswire
CytoSorbents Reports Second Quarter 2024 Financial and Operational Results
From CytoSorbents
Via GlobeNewswire
CytoSorbents Appoints Peter J. Mariani Chief Financial Officer
CytoSorbents CFO Kathleen P. Bloch Retires 
From CytoSorbents
Via GlobeNewswire
CytoSorbents to Report Second Quarter 2024 Operating and Financial Results
From CytoSorbents
Via GlobeNewswire
CytoSorbents Announces Compliance with Nasdaq Minimum Bid Price Requirement
From CytoSorbents
Via GlobeNewswire
CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website
“Working to Save Lives Together” Theme Highlights Two Decades of Successful Collaboration with the International Medical and Research Communities to Help Patients Survive Life-Threatening Illnesses 
From CytoSorbents
Via GlobeNewswire
CytoSorbents to Present at the Inaugural American Association of Physicians of Indian Origin (AAPI) World Health Congress
From CytoSorbents
Via GlobeNewswire
CytoSorbents Announces the Launch and Immediate Availability of the PuriFi™ Blood Pump in the European Union
By enabling more rapid and easy treatment, PuriFi is expected to increase the demand and sales of CytoSorbents’ leading CytoSorb® blood purification cartridge for critically ill patients in the... 
From CytoSorbents
Via GlobeNewswire
CytoSorbents Secures $20 Million Credit Facility
Credit facility provides timely non-dilutive capital to support ongoing global commercialization of CytoSorb® as well as regulatory submissions and potential commercialization plans for DrugSorb™-ATR... 
From CytoSorbents
Via GlobeNewswire
CytoSorbents to Host its 2024 Virtual Annual Stockholders Meeting
From CytoSorbents
Via GlobeNewswire
CytoSorbents Announces Regulatory Approval of CytoSorb® in Taiwan
Brings a powerful blood purification technology used to treat critically ill and cardiac surgery patients in nearly a quarter million treatments across 75 countries to date to one of the most... 
From CytoSorbents
Via GlobeNewswire
CytoSorbents STAR Registry Data on Patients on Ticagrelor Undergoing CABG Surgery with CytoSorb Presented at EuroPCR 2024. Named Top Five Finalist for Best Scientific Abstract
From CytoSorbents
Via GlobeNewswire
CytoSorbents Reports First Quarter 2024 Results
From CytoSorbents
Via GlobeNewswire
CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe
From CytoSorbents
Via GlobeNewswire
CytoSorbents to Report First Quarter 2024 Operating and Financial Results
From CytoSorbents
Via GlobeNewswire
STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting
From CytoSorbents
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.